ArticleCancer letters2021
The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapy.
Sashi Kandel et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
113 papers cite itlatest 60 shown
this paperpooled ittrialcites it